Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Antimicrobial Chemotherapy"
DOI: 10.1093/jac/dkac266
Abstract: Abstract Background The COVER trial evaluated whether nitazoxanide or sofosbuvir/daclatasvir could lower the risk of SARS-CoV-2 infection. Nitazoxanide was selected given its favourable pharmacokinetics and in vitro antiviral effects against SARS-CoV-2. Sofosbuvir/daclatasvir had shown favourable… read more here.
Keywords: sofosbuvir daclatasvir; infection; nitazoxanide sofosbuvir; sars cov ... See more keywords